Kim Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kim Le has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jennitte Stevens
Drug Substance Technologies, Amgen, Inc., Thousand Oaks, CA, USA
2 shared publications - Cenk Undey
Amgen, Inc., Thousand Oaks, USA
1 shared publication Christopher Tan
Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
1 shared publication- Erdal Oruklu
Department of Electrical and Computer Engineering, Illinois Institute of Technology, 3301 S. Dearborn St., Chicago, IL 60616, USA
1 shared publication - Ewelina Zasadzinska
Drug Substance Technologies, Process Development Amgen Inc., One Amgen Center Drive Thousand Oaks California USA
1 shared publication - Hedieh Barkhordarian
Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
1 shared publication
Latest Publications
- 24 July 2024
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (8) , 1659-1669
Cytopathic Effect Detection and Clonal Selection using Deep Learning
- 24 July 2024
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (8) , 1659-1669
Cytopathic Effect Detection and Clonal Selection using Deep Learning
- Open Access
- 28 July 2021
- Published by Wiley in Biotechnology Progress
- Vol. 37 (6) , e3192
Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability.
- 28 July 2021
- Published by Wiley in Biotechnology Progress
- Vol. 37 (6) , e3192
Open AccessMicrofluidic chip‐based single‐cell cloning to accelerate biologic production timelines
Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability.
- Open Access
- 19 September 2018
- Published by Wiley in Biotechnology Progress
- Vol. 34 (6) , 1438-1446
A novel mammalian cell line development platform utilizing nanofluidics and optoelectro positioning technology
Generating a highly productive cell line is resource intensive and typically involves long timelines because of the need to screen large numbers of candidates in protein production studies. This has led to miniaturization and automation strategies to allow for reductions in resources and higher throughput. Current approaches rely on the use of standard cell culture vessels and bulky liquid handling equipment. New nanofludic technologies offer novel solutions to surpass these limits, further miniaturizing cell culture volumes (10 5 times smaller) by growing cells on custom nanofluidic chips. Berkeley Lights’ OptoElectro Positioning technology projects light patterns to activate photoconductors that gently repel cells to manipulate single cells on nanofluidic culturing chips. Using a fully integrated technology platform (Beacon), common cell culture tasks can be programmed through software, allowing maintenance and analysis of thousands of cell lines in parallel on a single chip. Here, we describe the ability to perform key cell line development work on the Beacon platform. We demonstrate that commercial production Chinese hamster ovary cell lines can be isolated, cultured, screened, and exported at high efficiency. We compare this process head to head with a FACS‐enabled microtiter plate‐based workflow and demonstrate generation of comparable clonal cell lines with reduced resources. © 2018 American Institute of Chemical Engineers Biotechnol. Prog ., 34:1438–1446, 2018
- 19 September 2018
- Published by Wiley in Biotechnology Progress
- Vol. 34 (6) , 1438-1446
Open AccessA novel mammalian cell line development platform utilizing nanofluidics and optoelectro positioning technology
Generating a highly productive cell line is resource intensive and typically involves long timelines because of the need to screen large numbers of candidates in protein production studies. This has led to miniaturization and automation strategies to allow for reductions in resources and higher throughput. Current approaches rely on the use of standard cell culture vessels and bulky liquid handling equipment. New nanofludic technologies offer novel solutions to surpass these limits, further miniaturizing cell culture volumes (10 5 times smaller) by growing cells on custom nanofluidic chips. Berkeley Lights’ OptoElectro Positioning technology projects light patterns to activate photoconductors that gently repel cells to manipulate single cells on nanofluidic culturing chips. Using a fully integrated technology platform (Beacon), common cell culture tasks can be programmed through software, allowing maintenance and analysis of thousands of cell lines in parallel on a single chip. Here, we describe the ability to perform key cell line development work on the Beacon platform. We demonstrate that commercial production Chinese hamster ovary cell lines can be isolated, cultured, screened, and exported at high efficiency. We compare this process head to head with a FACS‐enabled microtiter plate‐based workflow and demonstrate generation of comparable clonal cell lines with reduced resources. © 2018 American Institute of Chemical Engineers Biotechnol. Prog ., 34:1438–1446, 2018